Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00413166 | All-trans Retinoic Acid, and Arsenic +/- Idarubicin | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01392989 | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | completed | Phase 2 | 44 | Everett MeyerOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01175785 |
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies |
| completed |
| Phase 2 |
| 15 |
| Nohla Therapeutics, Inc.INDUSTRY |
| 1 |
| Mar 5, 2019 |
| clinicaltrials |
| NCT00416598 | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 546 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00766116 | Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 50 | University of California, San DiegoOTHER | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01687387 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)(EFFIKIR) | completed | Phase 2 | 152 | Innate PharmaINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01729845 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01807598 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 10 | Jason Robert GotlibOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02296242 | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 53 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01408563 | Reduced Intensity Double Umbilical Cord Blood Transplantation | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | completed | Phase 2 | 279 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02019069 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 11 | Rondeep BrarOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01720264 | Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | completed | Phase 2 | 15 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00840346 | Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)(PANOBIDARA) | completed | Phase 1 / Phase 2 | 46 | PETHEMA FoundationOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00709592 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | completed | Phase 2 | 42 | Virginia Commonwealth UniversityOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00065143 | Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038597 | Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) | completed | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2018 | clinicaltrials |
| NCT01734304 | DC Vaccination for Postremission Therapy in AML | completed | Phase 1 / Phase 2 | 13 | Ludwig-Maximilians - University of MunichOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01025154 | Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | completed | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | completed | Phase 1 / Phase 2 | 7 | Cell Medica LtdINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT02282215 | Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia | completed | Phase 2 | 163 | Cellerant TherapeuticsINDUSTRY | 1 | Sep 27, 2018 | clinicaltrials |
| NCT00061581 | Experimental Bone Marrow Transplant Protocol | completed | Phase 2 | 14 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00233454 | Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia | completed | Phase 2 | 26 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01602952 | Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | completed | Phase 1 / Phase 2 | 85 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT01253447 | AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT00422591 | Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 2 | 175 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT00542971 | Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | completed | Phase 1 / Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype | completed | Phase 1 / Phase 2 | 37 | Hamid SayarOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00795002 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2018 | clinicaltrials |
| NCT01452646 | Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia(AML1310) | completed | Phase 2 | 515 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00467961 | Stem Cell Transplantation for Patients With Cancers of the Blood | completed | Phase 2 | 61 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00890929 | Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 45 | Stanford UniversityOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT00611247 | Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia | completed | Phase 2 | 42 | Bruno C. MedeirosOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00070135 | Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission | completed | Phase 2 | 121 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01994837 | A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 32 | AbbVieINDUSTRY | 0 | Jun 6, 2018 | clinicaltrials |
| NCT02210858 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00666588 | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 3 | May 22, 2018 | clinicaltrials |
| NCT00830518 | A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome | completed | Phase 2 | 57 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 11, 2018 | clinicaltrials |
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD(IL2 for GVHD) | completed | Phase 2 | 25 | Baylor College of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT01999413 | Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients(FAMYLY) | completed | Phase 2 | 30 | French Innovative Leukemia OrganisationOTHER | 1 | Apr 27, 2018 | clinicaltrials |
| NCT00357032 | PXD101 in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2018 | clinicaltrials |
| NCT00602225 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02395822 | MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients | completed | Phase 2 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01491958 | Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation | completed | Phase 2 | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2018 | clinicaltrials |
Data updated 23 days agoSource updated May 7, 2019source: clinicaltrials